TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 342625

Group type: EXPERIMENTAL
Intervention: Bivalent influenza A virus vaccines (200 or 400 CCA units of A/New Jersey/8/76 and A/Victoria/3/75)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Bivalent influenza A virus vaccines
Number of subjects: 234
Study: 30967436

Group type: EXPERIMENTAL
Intervention: Fish oil + placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Probiotics + placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fish oil + probiotics
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 439
Study: 25562711

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 59
Study: 23950585

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg intravenously once monthly (infusion every 4 weeks)
Number of subjects: 22
Study: 21429078

Group type: EXPERIMENTAL
Intervention: Birth ball usage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 19625629

Group type: EXPERIMENTAL
Intervention: Palosuran (5 to 2000 mg, oral doses)
Number of subjects: 72
Study: 17445284

Group type: EXPERIMENTAL
Intervention: 5 g high molecular weight (HMW) BBG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 5 g low molecular weight (LMW) BBG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 3 g high molecular weight (HMW) BBG
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 3 g low molecular weight (LMW) BBG
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study: 15119878

Group type: EXPERIMENTAL
Intervention: Permanent silicone‐based resilient denture liner (SR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin (AR)
Number of subjects: 28
Study: 11556937

Group type: EXPERIMENTAL
Intervention: General Medicine Clinic (GMC) with HIV-related training and evidence-based practice guidelines
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: General Medicine Clinic (GMC)
Number of subjects: 214
Study: 9623507

Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antigen-stimulated leukocyte supernatants
Number of subjects: 20
Study: 8162723

Group type: EXPERIMENTAL
Intervention: Outpatient pulmonary rehabilitation (OPR) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (waiting period of 6 weeks)
Number of subjects: 20
Study: 3348665

Group type: EXPERIMENTAL
Intervention: Long term ventilation of at least one ear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myringotomy for diagnosis
Number of subjects: 0
Study: 30741655

Group type: EXPERIMENTAL
Intervention: Telerounding in addition to standard rounds
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard rounds
Number of subjects: 80
Study: 30052097

Group type: EXPERIMENTAL
Intervention: Mild processing (slow time constants, disabled frequency lowering)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strong processing (fast time constants, frequency lowering enabled)
Number of subjects: 40
Study: 26631833

Group type: EXPERIMENTAL
Intervention: Targeted decolonisation with chlorhexidine and mupirocin
Number of subjects: 122646

Group type: EXPERIMENTAL
Intervention: Universal decolonisation with chlorhexidine and mupirocin
Number of subjects: 122646

Group type: COMPARATOR
Intervention: Screening and isolation
Number of subjects: 122646
Study: 25277343

Group type: EXPERIMENTAL
Intervention: Manual CPR
Number of subjects: 222

Group type: COMPARATOR
Intervention: Mechanical CPR
Number of subjects: 222
Study: 22360333

Group type: EXPERIMENTAL
Intervention: P‐3075 cream (5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan) applied twice daily for 4 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: P‐3075 cream (5% potassium azeloyl diglycinate and 1% hydroxypropyl chitosan)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 42
Study: 19217329

Group type: EXPERIMENTAL
Intervention: Cold pain sensitivity in women
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Heat pain sensitivity in women
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ischemic pain sensitivity in women
Number of subjects: 97

Group type: COMPARATOR
Intervention: Menstrual cycle influence on pain perception
Number of subjects: 97

Group type: COMPARATOR
Intervention: Gender differences in pain sensitivity
Number of subjects: 97
Study: 17426086

Group type: EXPERIMENTAL
Intervention: Physiological testosterone administration, 300 mug daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 16330295

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin (1.25 mg/250 mg BID for 6 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg) and Glyburide/Metformin coadministered
Number of subjects: 24
Study: 12167274

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) 100 mg bid SC injection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) 50 mg bid SC injection
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) continuous subcutaneous infusion (CSI) 12.5, 25, 50 or 100 mg/day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) subcutaneous injection (50 or 100 mg twice daily)
Number of subjects: 78
Study: 10203570

Group type: EXPERIMENTAL
Intervention: Meal A (600 g spinach)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meal B (300 g spinach)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meal C (0.4 mg folic acid in water)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meal D (folate-free control meal)
Number of subjects: 20
Study: 7607966

Group type: COMPARATOR
Intervention: Conventional fractionation (once daily 1.8‐2.0 Gy)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hyperfractionated split‐course irradiation (twice daily 1.6 Gy)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Definitive radiotherapy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 177

Group type: COMPARATOR
Intervention: Resection plus postoperative irradiation
Number of subjects: 177
Study: 2393075

Group type: EXPERIMENTAL
Intervention: 1 mg alfentanil (A1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2 mg alfentanil (A2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 3 mg alfentanil (A3)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 681295

Group type: EXPERIMENTAL
Intervention: amoxapine (300 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: amitriptyline (150 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: amoxapine
Number of subjects: 61

Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: amoxapine and amitriptyline
Number of subjects: 61
Study: 31639034

Group type: EXPERIMENTAL
Intervention: tofacitinib monotherapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: tofacitinib with methotrexate (MTX)
Number of subjects: 109

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR])
Number of subjects: 109
Study: 27868194

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (300 IU/kg/day, not to exceed 5,000 IU/day)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 26714164

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg kg(‐1) loading dose followed by 5 weekly 2 mg kg(‐1) doses)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 79
Study: 23749059

Group type: EXPERIMENTAL
Intervention: Inexpensive general-purpose LED headlight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purpose-built surgical LED headlight
Number of subjects: 0
Study: 22223196

Group type: EXPERIMENTAL
Intervention: Staff group (SG)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Peer-assisted learning group (PG)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Overall satisfaction with teaching environment
Number of subjects: 292

Group type: COMPARATOR
Intervention: Peer-assisted learning system (PAL)
Number of subjects: 292
Study: 20623180

Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment in HER2-positive patients
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NT)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy sHER2 levels
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: sHER2 cut-off level of 10 ng/ml
Number of subjects: 175

Group type: COMPARATOR
Intervention: sHER2 levels in HER2-negative patients
Number of subjects: 175
Study: 17624687

Group type: EXPERIMENTAL
Intervention: High dose diazepam (40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High dose opioid administration (150% normal dose)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (0 mg diazepam)
Number of subjects: 11
Study: 15886441

Group type: EXPERIMENTAL
Intervention: ACWD (automatic detection of cardiac waves boundaries)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ACWD
Number of subjects: 49
Study: 16625983

Group type: EXPERIMENTAL
Intervention: H. pylori eradication (1-week omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole group (1-week omeprazole 20 mg twice daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole group
Number of subjects: 100
Study: 11307252

Group type: EXPERIMENTAL
Intervention: 3% NaOCl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anolyte neutral cathodic (ANC) (300 mg L‐1 of active chlorine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of anolyte ANC and catholyte
Number of subjects: 20

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaOCl
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of ANC and catholyte
Number of subjects: 20
Study: 9122640

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration salt (ORS) solution (sodium 67, potassium 20, chloride 66, citrate 7, glucose 89 mmol/l, osmolality 249 mOsmol/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration salt (ORS) solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (hyperosmolar WHO/UNICEF ORS)
Number of subjects: 34
Study: 2060161

Group type: EXPERIMENTAL
Intervention: Tenoxicam (TNX) 20 mg once a day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ketoprofen (KPF) 100 mg twice a day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both TNX and KPF groups
Number of subjects: 13
Study: 6519170

Group type: EXPERIMENTAL
Intervention: Biperiden (4 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30608419

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided pulsed radiofrequency (UGPRF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham ultrasound-guided pulsed radiofrequency
Number of subjects: 136
Study: 30062516

Group type: EXPERIMENTAL
Intervention: Slow vital capacity maneuver
Number of subjects: 57

Group type: COMPARATOR
Intervention: Deflation maneuver
Number of subjects: 57
Study: 27412394

Group type: EXPERIMENTAL
Intervention: Oncologists with higher EOL care score (median 7)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Oncologists with higher EOL care score
Number of subjects: 182
Study: 24271261

Group type: EXPERIMENTAL
Intervention: Synbiotic food (1 × 10⁷ CFU Lactobacillus sporogenes and 0.04 g inulin HPX/g) consumed two times a day for 9 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control food consumed two times a day for 9 weeks
Number of subjects: 52
Study: 23394513

Group type: EXPERIMENTAL
Intervention: Fexofenadine at 180 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Fexofenadine at fourfold dose
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (allergic rhinitis)
Number of subjects: 111
Study: 19549211

Group type: EXPERIMENTAL
Intervention: Voice therapy and omeprazole (20 mg bid)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 32
Study: 18771886

Group type: EXPERIMENTAL
Intervention: Endovascular revascularization and best medical treatment (group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Best medical treatment only (group B)
Number of subjects: 33
Study: 15977693

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (20 units)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 50
Study: 12644777

Group type: EXPERIMENTAL
Intervention: Questionnaire
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pedigree interview
Number of subjects: 78

Group type: COMPARATOR
Intervention: Chart review
Number of subjects: 78
Study: 10551919

Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg (group-D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg (group-M)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (group-P)
Number of subjects: 120
Study: 8916058

Group type: EXPERIMENTAL
Intervention: Intravenous morphine premedication
Number of subjects: 18

Group type: COMPARATOR
Intervention: No morphine
Number of subjects: 18
Study: 1984988

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intermittent positive pressure breathing (IPPB)
Number of subjects: 52
Study: 30913472

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control condition (publicly available resources)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PDA in non-specialist setting
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control in non-specialist setting
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PDA in specialist setting
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control in specialist setting
Number of subjects: 96
Study: 28664342

Group type: EXPERIMENTAL
Intervention: Fish oil therapy (3.6 g of EPA and DHA)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fish oil therapy
Number of subjects: 105
Study: 26102298

Group type: EXPERIMENTAL
Intervention: Automated Telephone Self-Management Support (ATSM)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 362
Study: 23496277

Group type: COMPARATOR
Intervention: Delivery at 37 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Delivery at 38 weeks
Number of subjects: 69
Study: 21041485

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment in pregnancy (IPTp)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Placental infection at delivery
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Matched infections
Number of subjects: 402
Study: 19412007

Group type: EXPERIMENTAL
Intervention: Oats
Number of subjects: 23

Group type: COMPARATOR
Intervention: Gluten (wheat, rye, barley)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oats (after gluten exclusion)
Number of subjects: 23
Study: 17242315

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mug/d)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 15491374

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve (B. breve) supplement, 1.6 x 10(8) cells, twice a day, starting from several hours after birth (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve (B. breve) supplement, 1.6 x 10(8) cells, twice a day, starting 24 hours after birth (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group C), no supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve (B. breve) supplement, Group A vs Group B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve (B. breve) supplement, Group A
Number of subjects: 0
Study: 12575591

Group type: EXPERIMENTAL
Intervention: Compound Salvia Injection (CSI) added to conventional treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 60
Study: 9595973

Group type: EXPERIMENTAL
Intervention: IFN-beta-1a (Avonex; Biogen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-beta-1b
Number of subjects: 0
Study: 7887107

Group type: COMPARATOR
Intervention: HF group receiving high dose fentanyl (55 micrograms.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HF+TEA group receiving high dose fentanyl (55 micrograms.kg‐1) + TEA with 10 ml bupivacain 5 mg.ml‐1, followed by 4 ml every hour
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LF+TEA group receiving low dose fentanyl (15 micrograms.kg‐1) + TEA
Number of subjects: 30
Study: 2463559

Group type: EXPERIMENTAL
Intervention: Exercise tests at 50, 100, 150, or 200 W for 30 seconds
Number of subjects: 4
Study: 31922424

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31477164

Group type: EXPERIMENTAL
Intervention: Peer education intervention (up to two groups per puskesmas, led by trained individuals with diabetes, sessions held monthly for 18 months)
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 534
Study: 28653674

Group type: EXPERIMENTAL
Intervention: Orthotic therapeutic electrical stimulation (TES)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional training alone (Control)
Number of subjects: 29
Study: 25792638

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Cisplatin (80 mg·m(‐2) on day 1, every 3 weeks) and gemcitabine (1250 mg·m(‐2) on days 1 and 8, every 3 weeks) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Number of subjects: 224
Study: 24192471

Group type: EXPERIMENTAL
Intervention: First method of ILIH nerve block (needle inserted between outer 1/4 and inner 3/4 of a line connecting anterior‐superior iliac spine to umbilicus)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Second method of ILIH nerve block (needle inserted 1 cm medial and 1 cm superior to anterior‐superior iliac spine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both methods of ILIH nerve block
Number of subjects: 120
Study: 20658133

Group type: EXPERIMENTAL
Intervention: Grading system for scoring severity of MoM disease on MRI
Number of subjects: 59
Study: 19840379

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1.5, 3, 4.5, or 6 grams daily)
Number of subjects: 10
Study: 16930141

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg single dose on day 1 post-transplant)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg daily subcutaneous injections starting on day 5 post-transplant)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 37

Group type: COMPARATOR
Intervention: Filgrastim
Number of subjects: 37
Study: 15191542

Group type: EXPERIMENTAL
Intervention: Topical application of benzophenone-3 (BP-3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical application of octyl-methoxycinnamate (OMC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical application of 3-(4-methyl-benzylidene) camphor (4-MBC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical application of sunscreens (BP-3, OMC, 4-MBC)
Number of subjects: 32
Study: 11355124

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions identified by ICU physicians as having been tested by RCTs
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Interventions believed to improve survival
Number of subjects: 446
Study: 9443587

Group type: EXPERIMENTAL
Intervention: Dopamine precursor (L-DOPA) - 4 mg/kg Sinemet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Serotonin antagonist (Ritanserin) - 0.3 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8440859

Group type: EXPERIMENTAL
Intervention: Balance Training
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Tai Chi Quan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Group (Discussion Topics)
Number of subjects: 200
Study: 3449801

Group type: EXPERIMENTAL
Intervention: Trial A (exercise at 40% Wmax for 3 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Trial B (rest for 3 h)
Number of subjects: 7
Study: 31851017

Group type: EXPERIMENTAL
Intervention: High-density fractional CO2 laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medium-density fractional CO2 laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-density fractional CO2 laser
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Histopathological evaluation with high-density laser treatment
Number of subjects: 25
Study: 30728003

Group type: EXPERIMENTAL
Intervention: ART+C (1 mg/kg corticosteroids)
Number of subjects: 38

Group type: COMPARATOR
Intervention: ART Alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: ART+C
Number of subjects: 38
Study: 28034773

Group type: EXPERIMENTAL
Intervention: Ligasure™ vascular sealing system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional method with silk suture ligation
Number of subjects: 80
Study: 26437498

Group type: EXPERIMENTAL
Intervention: Anhydrous dentifrice containing 0.454% w/w stannous fluoride
Number of subjects: 119

Group type: COMPARATOR
Intervention: Negative control dentifrice containing 1,000 ppm fluoride, as sodium monofluorophosphate
Number of subjects: 119
Study: 23483343

Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 33
Study: 21439042

Group type: EXPERIMENTAL
Intervention: Mums4Mums telephone support intervention delivered by trained peer-supporters over a period of four months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mums4Mums telephone support intervention
Number of subjects: 0
Study: 20073428

Group type: EXPERIMENTAL
Intervention: Pre-diabetic group
Number of subjects: 656

Group type: COMPARATOR
Intervention: Normoglucemic group
Number of subjects: 656